Shares of Lantheus Holdings Inc (NASDAQ:LNTH) declined roughly 0.7% in after-hours trading Friday after the U.S. Food and Drug Administration issued a Complete Response Letter notifying the company that its New Drug Application for LNTH-2501 cannot be approved at this time.
The FDA attributed the refusal to unresolved manufacturing-related conditions discovered at a third-party facility responsible for drug product manufacturing. The agency said those facility inspection issues must be satisfactorily addressed before the LNTH-2501 application can move to approval. As a result, the application will not be approved by the June 29, 2026 action date.
Importantly, the Complete Response Letter did not identify any problems with the clinical data Lantheus submitted, nor did it raise issues tied to the safety or efficacy profile of LNTH-2501. The candidate imaging agent is intended to target somatostatin receptor-positive neuroendocrine tumors and uses Gallium 68 edotreotide.
In response to the FDA communication, Lantheus leadership reiterated confidence in the product. "We remain confident in LNTH-2501 and are committed to bringing this imaging agent to NETs patients and healthcare providers as soon as possible," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer at Lantheus. "The feedback received from the FDA relates solely to our third-party manufacturer, and not to the clinical performance of the product."
LNTH-2501 is supplied as a two-vial kit intended for radiopharmacies to prepare a Ga 68 edotreotide injection using gallium from an on-site generator. The product does not currently hold FDA approval and is not on sale in the United States.
Lantheus said it is coordinating with its manufacturing partner and the FDA to resolve the identified facility-related conditions and to advance the program toward potential approval once the issues are addressed.
Summary
The FDA issued a Complete Response Letter for Lantheus’ LNTH-2501 New Drug Application, citing unresolved inspection-related conditions at a third-party drug product manufacturer. The clinical data and safety or efficacy were not flagged by the agency. Lantheus is working with its manufacturing partner and the FDA to resolve the issues.
Key points
- FDA issued a Complete Response Letter blocking approval of LNTH-2501 due to manufacturing-related conditions at a third-party facility.
- The agency did not cite concerns about the clinical data, safety, or efficacy of LNTH-2501.
- Lantheus is engaging with its manufacturing partner and the FDA to address the facility inspection issues; the product remains unapproved and not available for sale in the U.S.
Risks and uncertainties
- Timing risk: The application will not be approved by the June 29, 2026 action date unless facility-related conditions are resolved to the FDA's satisfaction.
- Operational risk: Continued unresolved issues at the third-party manufacturing facility could delay approval further and affect program timelines.
- Commercial availability risk: Because LNTH-2501 is not approved, it is not available for sale in the United States until regulatory concerns are cleared.
Investors and market participants in the healthcare and specialty diagnostics sectors will be watching for updates on remedial actions at the implicated manufacturing site and any further communications from the FDA regarding necessary steps to clear the inspection-related conditions.